Payers

Alzheimer’s Agitation Moves Closer to a Phase 2 Readout

ALS Survival Data Return to the Evidence Debate

Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits

WHO is preparing to ration the obesity drug revolution before it becomes another access disaster

CAR-T Starts Moving From Factory Medicine to In-Patient Engineering

AML’s Frontline Future Starts With Finding the Mutation Fast

FSHD Gets a Stronger Biological Signal

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
